Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07066657 | A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | PHASE1 | RECRUITING | 405 | — | — | Jul 25, 2025 | Dec 1, 2030 | Jun 4, 2026 | 20 | United States, China |
Adverse events that are fatal, life-threatening, or result in hospitalization or prolonged hospitalization, persistent or significant disability/incapacity/substantial disruption of the ability to lead a normal life, congenital anomaly/birth defect or major medical events or reactions
AEs that occur or worsen on or after the first dose of study treatment
Any reaction, side effect, or untoward event that occurs during the course of the clinical trial is considered related to the study drug.
ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed according to RECIST v1.1.
| Arm | Type | Description |
|---|---|---|
| MRG007 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MRG007 | DRUG | MRG007 will be administrated as specified in the protocol. |
1. Willing to sign the informed consent form and follow the requirements specified in the protocol. 2. Life expectancy ≥ 3 months. 3. Tumor specimen available for CDH17 testing, or agree to biopsy at baseline. 4. Patients with histologically and cytologically confirmed advanced or metastatic solid t...